Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Covered in this story
Analyst targets on Summit Therapeutics
- Bernstein: $17.3 → $11.9 by Oct 2027 · Market Perform via Investing.com
- Citizens JMP: $16.9 → $40 by Sep 2027 · Market Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $SMMT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Summit Therapeutics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.